[1] |
YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei.
Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
|
[2] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
[3] |
LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke.
A bioequivalence study of generic and brand clozapine in schizophrenic patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
|
[4] |
LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai.
Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
|
[5] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
[6] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
[7] |
GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing.
Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
|
[8] |
WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei.
Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
|
[9] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
[10] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|
[11] |
SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong.
A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
|
[12] |
GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong.
Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 56-62.
|
[13] |
HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang.
Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
|
[14] |
CAI Mingmin, SHAO Jing, TANG Lu, SUN Qiuyue, DOU Ting, QIAN Wei, WANG Huiping.
Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 70-76.
|
[15] |
ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang.
Research progress of PARP inhibitors in pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
|